Nesya Goris has a Master in Biology (KU leuven, 2002) with a PhD in veterinary sciences obtained at the UGent in 2008. Nesya is co-founder and chief development officer at ViroVet, a Belgian SME that spun-out of the Rega Institute of the KU Leuven. ViroVet focuses its R&D efforts on the development of antiviral drugs and innovative vaccines for infectious diseases of livestock. Nesya has held and holds various senior research, regulatory and management positions at animal health start-ups such as Okapi Sciences, Aratana Therapeutics, ViroVet and Animab, the latter being a recent spin-off from VIB aimed at developing a new class of oral antibodies to ensure the intestinal health of piglets. Nesya is a Board Member of Flanders Vaccine as well as an Editor for the journal Antiviral Research.